"All in all, I believe that BLRX has a very good risk/reward profile in the biotech space at the moment, with upside of at least 50% in a 4-5 year window at a very conservative estimation. "
LONDON, June 11, 2015 /PRNewswire/ --
Stem cell specialists for healthcare - discover what the future holds for those companies.
Who are the top stem cell developers and producers? And what are their sales outlooks? Visiongain's new report shows you their potentials from 2015. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts.
That way you find data and analysis on cellular technologies transforming human medicine. Our study analyses 23 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain, discovering their potentials.
Companies based in Europe and Israel- what successes can they achieve?
Our analysis also shows you progress and prospects for seven European and Israeli companies:
• Cardio3 BioSciences
• Gamida Cell
• Cell Cure Neurosciences
• Pluristem Therapeutics.
"TIS and Fujitsu share a strong, long-lived partnership based on many years of providing high-performance document capture solutions to enterprises worldwide," said Gordon Sellers, vice president, strategy and product management, Top Image Systems. "We are certain that the seamless integration between eFLOW and PaperStream IP, which enables highly accurate end-to-end document capture and processing for maximum straight through processing, will drive new joint business opportunities for Top Image Systems and Fujitsu, especially in the U.S."
Analysts at B. Riley reiterated a “buy” rating and set a $17.75 price target on shares of Supercom in a research note on Thursday, May 28th. Analysts at Singular Research initiated coverage on shares of Supercom in a research note on Tuesday, March 31st. They set a “buy” rating and a $13.25 price target on the stock. Finally, analysts at Feltl & Co. initiated coverage on shares of Supercom in a research note on Friday, March 27th. They set a “strong-buy” rating and a $16.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Supercom currently has a consensus rating of “Buy” and a consensus target price of $15.17.
Supercom (NASDAQ:SPCB) was upgraded by research analysts at TheStreet from a “hold” rating to a “buy” rating in a report released on Tuesday.
A number of other firms have also recently commented on SPCB. Analysts at Zacks upgraded shares of Supercom from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday.